mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Majumder, Pradip K, Febbo, Phillip G, Bikoff, Rachel, Berger, Raanan, Xue, Qi, McMahon, Louis M, Manola, Judith, Brugarolas, James +5 more·2004·Nature Medicine
DOI 10.1038/nm1052

Cited by (962)

Items 101–200 of 962

  1. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
    Rhonda Lynn Bitting, Andrew J. Armstrong · 2013 · Endocrine Related Cancer
  2. Cancer recurrence after surgery: Direct and indirect effects of anesthetic agents*
    Aniket N. Tavare, Nicholas J. S. Perry, Laura L. Benzonana, Masao Takata, Daqing Ma · 2011 · International Journal of Cancer
  3. New aspects of the Warburg effect in cancer cell biology
    Steven J. Bensinger, Heather R. Christofk · 2012 · Seminars in Cell and Developmental Biology
  4. The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer
    Fabrizio Fontana, Gaia Giannitti, Sara Marchesi, Patrízia Limonta · 2024 · International Journal of Biological Sciences
  5. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity
    Biswanath Majumder, Baraneedharan Ulaganathan, Saravanan Thiyagarajan, Padhma Radhakrishnan, Harikrishna Narasimhan, Muthu Dhandapani, Nilesh Brijwani, Dency D. Pinto, Arun Prasath, Basavaraja Shanthappa et al. · 2015 · Nature Communications
  6. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
    Maisa Yoshimoto, Isabela Werneck da Cunha, Renata A. Coudry, F.P. Fonseca, César Torres, Fernando Augusto Soares, Jeremy Andrew Squire · 2007 · British Journal of Cancer
  7. The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila
    Jan H. Reiling, Ernst Hafen · 2004 · Genes & Development
  8. Metformin and cancer: new applications for an old drug
    Taxiarchis Kourelis, Robert David Siegel · 2011 · Medical Oncology
  9. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas
    Eva Hernando, Elizabeth Charytonowicz, Maria E. Dudas, Sílvia Menéndez, Igor Matushansky, Joslyn E. Mills, Nicholas D. Socci, Nille Behrendt, Li Ma, Robert G. Maki et al. · 2007 · Nature Medicine
  10. Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
    Todd Matthew Morgan, Theodore D. Koreckij, Eva Corey · 2009 · Current Cancer Drug Targets
  11. Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
    Karen W L Yee, Zhihong Zeng, Marina Y Konopleva, Srđan Verstovšek, Farhad Ravandi, Alessandra Ferrajoli, Deborah Ann Thomas, William G. Wierda, Efrosyni Apostolidou, Maher X. Albitar et al. · 2006 · Clinical Cancer Research
  12. Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer
    Minru Liao, Dahong Yao, Lifeng Wu, Chaodan Luo, Zhiwen Wang, Jin Zhang, Bo Liu · 2023 · Acta Pharmaceutica Sinica B
  13. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors
    Xia, Yan, Choi, Hyun-Kyung, Lee, Kyeong · 2012 · European Journal of Medicinal Chemistry
  14. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome
    Maisa Yoshimoto, Anthony Michael Joshua, Isabela Werneck da Cunha, Renata A. Coudry, F.P. Fonseca, Olga Ludkovski, Maria Zieleńska, Fernando Augusto Soares, Jeremy Andrew Squire · 2008 · Modern Pathology
  15. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
    AndrewC Hsieh, Merritt P. Edlind · 2014 · Asian Journal of Andrology
  16. PTEN function in normal and neoplastic growth
    Lionel M.L. Chow, Suzanne J. Baker · 2006 · Cancer Letters
  17. Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
    Kazuhiro Tanaka, Ivan Babić, David A. Nathanson, David Akhavan, Deliang Guo, Beatrice Gini, Julie H. T. Dang, Shaojun Zhu, Huijun Yang, Jason De Jesus et al. · 2011 · Cancer Discovery
  18. AKT in cancer: new molecular insights and advances in drug development
    Mundi, Prabhjot S., Sachdev, Jasgit, McCourt, Carolyn, Kalinsky, Kevin · 2016 · British Journal of Clinical Pharmacology
  19. The PKB/AKT Pathway in Cancer
    Amancio Carnero · 2009 · Current Pharmaceutical Design
  20. mTORC 1 and mTORC 2 as regulators of cell metabolism in immunity
    Monika Linke, Stephanie Deborah Fritsch, Nyamdelger Sukhbaatar, Markus Hengstschläger, Thomas Weichhart · 2017 · FEBS Letters
  21. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward
    Gary J. Kelloff, Scott Michael Lippman, Andrew J. Dannenberg, Caroline C. Sigman, Homer L. Pearce, Brian J. Reid, Eva M. Szabo, Virgil Craig Jordan, Margaret R. Spitz, Gordon Brent Mills et al. · 2006 · Clinical Cancer Research
  22. The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease
    Claire Goul, Roberta Peruzzo, Roberto Zoncu · 2023 · Nature Reviews Molecular Cell Biology
  23. Development of HIF‐1 inhibitors for cancer therapy
    Onnis, Barbara, Rapisarda, Annamaria, Melillo, Giovanni · 2009 · Journal of Cellular and Molecular Medicine
  24. mTORC1 Signaling under Hypoxic Conditions Is Controlled by ATM-Dependent Phosphorylation of HIF-1α
    Cam, Hakan, Easton, John B., High, Anthony, Houghton, Peter J. · 2010 · Molecular Cell
  25. Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies
    Mans Broekgaarden, Ruud Weijer, Thomas M. van Gulik, Michael Richard Hamblin, Michal Heger · 2015 · Cancer and Metastasis Reviews
  26. Renal-Cell Carcinoma — Molecular Pathways and Therapies
    James Brugarolas · 2007 · New England Journal of Medicine
  27. mTOR-Raptor Binds and Activates SGK1 to Regulate p27 Phosphorylation
    Feng Hong, Michelle D. Larrea, Cheryl A. Doughty, David J. Kwiatkowski, Rachel M. Squillace, Joyce M. Slingerland · 2008 · Molecular Cell
  28. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
    Chad J. Creighton, Xiaoyong Fu, Bryan T. Hennessy, Angelo J Casa, Yiqun Zhang, Ana Maria Gonzalez-Angulo, Ana M. Lluch, Joe W. Gray, Powell H Brown, Susan Galloway Hilsenbeck et al. · 2010 · Breast Cancer Research
  29. Hypoxia-inducible factor-1 in human breast and prostate cancer
    Kevin Sean Kimbro, Jonathan W. Simons · 2006 · Endocrine Related Cancer
  30. Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN
    Igor Vivanco, Nicolaos Jay Palaskas, Chris Tran, Stephen P. Finn, Gad A. Getz, Norman J. Kennedy, Jing Jiao, J.A. Rose, Wanling Xie, Massimo F. Loda et al. · 2007 · Cancer Cell
  31. Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy
    Alex A. Adjei, Manuel M. Hidalgo · 2005 · Journal of Clinical Oncology
  32. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck
    Amornphimoltham, Panomwat, Patel, Vyomesh, Sodhi, Akrit, Nikitakis, Nikolaos G., Sauk, John J., Sausville, Edward A., Molinolo, Alfredo A., Gutkind, J. Silvio · 2005 · Cancer Research
  33. Amino Acid Signaling in TOR Activation
    Joungmok Kim, Kun‐Liang Guan · 2011 · Annual Review of Biochemistry
  34. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells
    Benjamin Ate Kefas, L. Comeau, N. Erdle, Elizabeth Anne Montgomery, Samson Amos, Benjamin W. Purow · 2010 · Neuro-Oncology
  35. RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model
    Seiji Mabuchi, Deborah A. Altomare, Mitchell Cheung, Lili Zhang, Poulikos I. Poulikakos, Harvey H. Hensley, Russell J. Schilder, Robert F. Ozols, Joseph R. Testa · 2007 · Clinical Cancer Research
  36. Targeting hypoxia cell signaling for cancer therapy
    Melillo, Giovanni · 2007 · Cancer and Metastasis Reviews
  37. Metabolic transformation in cancer
    Daniel A. Tennant, Raúl V. Durán, Houda Boulahbel, Eyal Gottlieb · 2009 · Carcinogenesis
  38. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations
    Cedric Magaway, Eugene Kim, Estela Jacinto · 2019 · Cells
  39. Identification of a Novel Small-Molecule Inhibitor of the Hypoxia-Inducible Factor 1 Pathway
    Chalet Tan, Rita G. de Noronha, Anthony J. Roecker, Beata Pyrzyńska, Fatima W. Khwaja, Zhaobin Zhang, Huanchun Zhang, Quincy Teng, Ainsley C. Nicholson, Paraskevi Giannakakou et al. · 2005 · Cancer Research
  40. Experimental models of hepatocellular carcinoma
    Philippa H. Newell, Augusto Villanueva, Scott L. Friedman, Kazuhiko Koike, Josep Maria Llovet · 2008 · Journal of Hepatology
  41. Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis
    Michail Ignatiadis, Sandeep Kumar Singhal, Christine Desmedt, Benjamin Haibe‐Kains, Carmen Criscitiello, Fabrice André, Sherene Loi, Martine J Piccart, Stefan Michiels, Christos P. Sotiriou · 2012 · Journal of Clinical Oncology
  42. PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer
    David J. Mulholland, Shoukat Dedhar, Hong Wu, Colleen C. Nelson · 2006 · Oncogene
  43. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer
    Thanakorn Pungsrinont, Julia Kallenbach, Aria Baniahmad · 2021 · International Journal of Molecular Sciences
  44. Extensions to gene set enrichment
    Zhen Jiang, Robert C. Gentleman · 2006 · Bioinformatics
  45. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges
    Muhammad Zaeem Noman, Meriem Hasmim, Audrey Lequeux, Malina Xiao, Caroline Duhem, Salem Chouaı̈b, Guy Berchem, Bassam Janji · 2019 · Cells
  46. The Genomic Analysis of Lactic Acidosis and Acidosis Response in Human Cancers
    Julia Ling-Yu Chen, Joseph E. Lucas, Thies Schroeder, Seiichi Mori, Jianli Wu, Joseph Roy Nevins, Mark W. Dewhirst, Mike West, Jen‐Tsan Chi · 2008 · PLoS Genetics
  47. DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses
    Sophie Vasseur, Samia Afzal, J. Tardivel‐Lacombe, David S. Park, Juan Iovanna, Tak W. Mak · 2009 · Proceedings of the National Academy of Sciences
  48. A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
    Manuel M. Hidalgo, Jan C. Buckner, Charles Erlichman, Marilyn S. Pollack, Joseph P Boni, Gary Dukart, Bonnie Marshall, Lisa A. Speicher, Laurence Moore, Eric Keith Rowinsky · 2006 · Clinical Cancer Research
  49. Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
    Chiaki Tanaka, Terence O’Reilly, John M. Kovarik, Nicholas Shand, Katharine Hazell, Ian Robert Judson, Éric Raymond, Sabine Zumstein-Mecker, Christine Stephan, Anne Boulay et al. · 2008 · Journal of Clinical Oncology
  50. Xenon Preconditioning Protects against Renal Ischemic-Reperfusion Injury via HIF-1α Activation
    Daqing Ma, T. L. Lim, Jing Xu, Haidy Tang, Yanjie Wan, Hailin Zhao, Mahmuda Hossain, Patrick Henry Maxwell, Mervyn Maze · 2009 · Journal of the American Society of Nephrology
  51. PIK3CA/PTEN Mutations and Akt Activation as Markers of Sensitivity to Allosteric mTOR inhibitors
    F. Meric-Bernstam, A. Akcakanat, Hui-Qin Chen, K. Do, T. Sangai, Farrell C. Adkins, A. González-Angulo, A. Rashid, K. Crosby, M. Dong et al. · 2012 · Clinical Cancer Research
  52. Isoflurane, a Commonly Used Volatile Anesthetic, Enhances Renal Cancer Growth and Malignant Potential via the Hypoxia-inducible Factor Cellular Signaling Pathway In Vitro
    Laura L. Benzonana, Nicholas J. S. Perry, Helena R. Watts, Bob Yang, Iain A. Perry, R. Charles Coombes, Masao Takata, Daqing Ma · 2013 · Anesthesiology
  53. mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome
    David B. Shackelford, Debbie S. Vasquez, Jacques Corbeil, Shulin Wu, Mathias Leblanc, Chin‐Lee Wu, David R. Vera, Reuben J. Shaw · 2009 · Proceedings of the National Academy of Sciences
  54. TORC1 Is Essential for NF1-Associated Malignancies
    Cory M. Johannessen, Bryan W. Johnson, Sybil M. Genther Williams, Annie W. Chan, Elizabeth E. Reczek, Ryan C. Lynch, Matthew J. Rioth, Andrea I. McClatchey, Sandra W. Ryeom, Karen M. Cichowski · 2008 · Current Biology
  55. Radiation, Inflammation, and Immune Responses in Cancer
    Gabriele Multhoff, Jürgen Radons · 2012 · Frontiers in Oncology
  56. Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis
    Peter Horak, Andrew Robert Crawford, Douangsone D. Vadysirisack, Zachary M. Nash, Maurice Phillip DeYoung, Dennis C. Sgroi, Leif William Ellisen · 2010 · Proceedings of the National Academy of Sciences
  57. Pyruvate kinase M2 at a glance
    Weiwei Yang, Zhimin Lu · 2015 · Journal of Cell Science
  58. mTOR Promotes Survival and Astrocytic Characteristics Induced by Pten/Akt Signaling in Glioblastoma
    Xiaoyi Hu, Pier Paolo Pandolfi, Yi Li, Jason A. Koutcher, Marc K. Rosenblum, Eric C. Holland · 2005 · Neoplasia
  59. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor
    Akrit Sodhi, Risa Chaisuparat, Jiadi Hu, Amanda K. Ramsdell, Brendan D. Manning, Edward A. Sausville, Earl T. Sawai, Alfredo Molinolo, Jorge Silvio Gutkind, Silvia Montaner · 2006 · Cancer Cell
  60. Comparative expression pathway analysis of human and canine mammary tumors
    Paolo Uva, Luigi Aurisicchio, James Watters, Andrey P. Loboda, Amit Kulkarni, John C. Castle, Fabio Palombo, Valentina Viti, Giuseppe Mesiti, Valentina Zappulli et al. · 2009 · BMC Genomics
  61. Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing
    Zimmer, Michael, Ebert, Benjamin L., Neil, Christopher, Brenner, Keith, Papaioannou, Ioannis, Melas, Antonia, Tolliday, Nicola, Lamb, Justin, Pantopoulos, Kostas, Golub, Todd et al. · 2008 · Molecular Cell
  62. Molecular imaging for personalized cancer care
    Moritz F. Kircher, Hedvig Hricak, Steven M. Larson · 2012 · Molecular Oncology
  63. mTOR signaling in glioblastoma: lessons learned from bench to bedside
    David Akhavan, Timothy Francis Cloughesy, Paul S. Mischel · 2010 · Neuro-Oncology
  64. Akt1 Activation Can Augment Hypoxia-Inducible Factor-1α Expression by Increasing Protein Translation through a Mammalian Target of Rapamycin–Independent Pathway
    Nabendu Pore, Zibin Jiang, Hui‐Kuo G. Shu, Eric J. Bernhard, Gary D. Kao, Amit M. Maity · 2006 · Molecular Cancer Research
  65. Rapamycin confers preconditioning-like protection against ischemia–reperfusion injury in isolated mouse heart and cardiomyocytes
    Shakil A. Khan, Fadi N. Salloum, Anindita Das, Lei Xi, George Wayne Vetrovec, Rakesh C. Kukreja · 2006 · Journal of Molecular and Cellular Cardiology
  66. Enhanced radiation damage of tumor vasculature by mTOR inhibitors
    Eric T. Shinohara, Carolyn Cao, K.J. Niermann, Yi Mu, Fenghua Zeng, Dennis E. Hallahan, Jiahong Lu · 2005 · Oncogene
  67. mTOR links oncogenic signaling to tumor cell metabolism
    Yecies, Jessica L., Manning, Brendan D. · 2011 · Journal of Molecular Medicine
  68. Regulation and function of pyruvate kinase M2 in cancer
    Weiwei Yang, Zhimin Lu · 2013 · Cancer Letters
  69. Role of long non-coding RNAs in glucose metabolism in cancer
    Chunmei Fan, Yanyan Tang, Jinpeng Wang, Fang Xiong, Can Jie Guo, Yumin Wang, Shanshan Zhang, Zhaojian Gong, Fang Wei, Liting Yang et al. · 2017 · Molecular Cancer
  70. Expression of mTOR signaling pathway markers in prostate cancer progression
    Celeste L. Kremer, Rob R. Klein, Jenny Mendelson, Walden Browne, Linda K. Samadzedeh, Kristie A. Vanpatten, Lindsey M. Highstrom, Gary Anthony Pestano, Raymond B. Nagle · 2006 · The Prostate
  71. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias
    Maisa Yoshimoto, Jean‐Claude Cutz, Paulo A.S. Nuin, Anthony Michael Joshua, Jane Bayani, Andrew John Evans, Maria Zieleńska, Jeremy Andrew Squire · 2006 · Cancer Genetics and Cytogenetics
  72. mTOR pathway in colorectal cancer: an update
    Maria Giovanna Francipane, Eric Lagasse · 2013 · Oncotarget
  73. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation
    Barbara Bedogni, Scott M. Welford, David Samuel Cassarino, Brian J. Nickoloff, Amato J. Giaccia, Marianne Broome Powell · 2005 · Cancer Cell
  74. A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression
    Pradip K. Majumder, Chiara Grisanzio, Fionnuala O’Connell, Marc Barry, Joseph M. Brito, Qing Xu, Isil Guney, Raanan Berger, Paula K. Herman, Rachel Bikoff et al. · 2008 · Cancer Cell
  75. Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer
    Phillip G. Febbo, Jerome P. Richie, Daniel J. George, Massimo F. Loda, Judith B. Manola, Sridhar Shankar, Agnieska Szot Barnes, Clare M. Tempany, William J. Catàlona, Philip W. Kantoff et al. · 2005 · Clinical Cancer Research
  76. A growing role for mTOR in promoting anabolic metabolism
    Jessica J. Howell, Stéphane J. H. Ricoult, Issam Ben‐Sahra, Brendan D. Manning · 2013 · Biochemical Society Transactions
  77. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(ε-caprolactone) micelles
    Marcus Laird Forrest, Chee-Youb Won, A. Waseem Malick, Glen S. Kwon · 2005 · Journal of Controlled Release
  78. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members
    Deborah Defeo-Jones, Stanley F. Barnett, Sheng Fu, Paula J. Hancock, Kathleen Haskell, Karen R. Leander, Elizabeth McAvoy, R. Robinson, Mark E. Duggan, Craig W. Lindsley et al. · 2005 · Molecular Cancer Therapeutics
  79. Genes and gene expression modules associated with caloric restriction and aging in the laboratory mouse
    Swindell, William R · 2009 · BMC Genomics
  80. Circulating microRNA Profiling Identifies a Subset of Metastatic Prostate Cancer Patients with Evidence of Cancer-Associated Hypoxia
    Heather H. Cheng, Patrick S. Mitchell, Evan M. Kroh, Alexander E. Dowell, Lisly J. Chery, Javed Siddiqui, Peter S. Nelson, Robert L. Vessella, Beatrice S. Knudsen, Arul M. Chinnaiyan et al. · 2013 · PLoS ONE
  81. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling
    Sang‐Hoon Sin, Debasmita Roy, Ling Wang, Michelle R. Staudt, Farnaz D. Fakhari, Dhavalkumar D. Patel, David H. Henry, William J. Harrington, Blossom Damania, Dirk P. Dittmer · 2006 · Blood
  82. Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
    Mark Frederick McCarty · 2004 · Integrative Cancer Therapies
  83. The HIF pathway in cancer
    Patrick Henry Maxwell · 2005 · Seminars in Cell and Developmental Biology
  84. Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy
    Giovanni Melillo · 2006 · Molecular Cancer Research
  85. Regulation of Akt signaling activation by ubiquitination
    Wei-Lei Yang, Ching-Yuan Wu, Juan Wu, Hui-Kuan Lin · 2010 · Cell Cycle
  86. How Can We Overcome Tumor Hypoxia in Radiation Therapy?
    Hiroshi Harada · 2011 · Journal of Radiation Research
  87. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
    Jean‐Charles Soria, Frances A. Shepherd, Jean‐Yves Douillard, J. Wolf, Giuseppe Giaccone, Lucio Crinò, Federico Cappuzzo, Shreya Sharma, S. H. Gross, Saša Dimitrijević et al. · 2009 · Annals of Oncology
  88. Mitochondrial Metabolism and Cancer
    Frank D. Weinberg, Navdeep S. Chandel · 2009 · Annals of the New York Academy of Sciences
  89. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in Apc Δ716 mice
    Teruaki Fujishita, Koji Aoki, Heidi A. Lane, Masahiro Aoki, Makoto Mark Taketo · 2008 · Proceedings of the National Academy of Sciences
  90. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes
    James Brugarolas, William G. Kaelin · 2004 · Cancer Cell
  91. Mechanisms of mTOR inhibitor resistance in cancer therapy
    Jennifer S. Carew, Kevin R. Kelly, Steffan T. Nawrocki · 2011 · Targeted Oncology
  92. Akt-dependent Activation of mTORC1 Complex Involves Phosphorylation of mTOR (Mammalian Target of Rapamycin) by IκB Kinase α (IKKα)
    Han C. Dan, Aaron Ebbs, Manolis Pasparakis, Terry Van Dyke, Daniela S. Daniela Sanchez Bassères, Albert S. Baldwin · 2014 · Journal of Biological Chemistry
  93. Transcriptional Control of Cellular Metabolism by mTOR Signaling
    Jessica L. Yecies, Brendan D. Manning · 2011 · Cancer Research
  94. Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors
    Maryam Fouladi, Fred H. Laningham, Jianrong Wu, Melinda A. O'Shaughnessy, Kristen Molina, Alberto Broniscer, Sheri L. Spunt, Inga Luckett, Clinton F. Stewart, Peter J. Houghton et al. · 2007 · Journal of Clinical Oncology
  95. TCR Engagement Increases Hypoxia-Inducible Factor-1α Protein Synthesis via Rapamycin-Sensitive Pathway under Hypoxic Conditions in Human Peripheral T Cells
    Nakamura, Hiroshi, Makino, Yuichi, Okamoto, Kensaku, Poellinger, Lorenz, Ohnuma, Kei, Morimoto, Chikao, Tanaka, Hirotoshi · 2005 · The Journal of Immunology
  96. mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
    Seiji Mabuchi, Chiaki Kawase, Deborah A. Altomare, Ken‐ichirou Morishige, Kenjiro Sawada, Masami Hayashi, Masahiko Tsujimoto, Mareo Yamoto, Andres J. Klein–Szanto, Russell J. Schilder et al. · 2009 · Clinical Cancer Research
  97. Soft tissue sarcomas with complex genomic profiles
    Louis Guillou, Alain Aurias · 2009 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  98. Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects
    Runze Shang, Shibin Qu, Desheng Wang · 2016 · World Journal of Gastroenterology
  99. Microenvironment and Radiation Therapy
    Michio Yoshimura, Satoshi Itasaka, Hiroshi Harada, Masahiro Hiraoka · 2012 · BioMed Research International
  100. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth
    Deborah A. Altomare, Huihong You, Guang‐Hui Xiao, Maria E. Ramos‐Niño, Kristine L. Skele, Assunta De Rienzo, Suresh C. Jhanwar, Brooke Taylor Mossman, Agnes B. Kane, Joseph R. Testa · 2005 · Oncogene